The media in this post is not displayed to visitors. To view it, please go to the original post.
Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.
The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.
#news #health #medicine #cholesterol #GeneTherapy #GeneEditing
